89 related articles for article (PubMed ID: 16139245)
21. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1.
Matsushita A; Götze T; Korc M
Cancer Res; 2007 Nov; 67(21):10309-16. PubMed ID: 17974973
[TBL] [Abstract][Full Text] [Related]
22. Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor.
Chen JH; Wu CW; Kao HL; Chang HM; Li AF; Liu TY; Chi CW
Cancer Lett; 2006 Aug; 239(2):263-70. PubMed ID: 16243430
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells.
Hara S; Nakashiro K; Klosek SK; Ishikawa T; Shintani S; Hamakawa H
Oral Oncol; 2006 Jul; 42(6):593-8. PubMed ID: 16469527
[TBL] [Abstract][Full Text] [Related]
24. Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells.
Hui AY; Meens JA; Schick C; Organ SL; Qiao H; Tremblay EA; Schaeffer E; Uniyal S; Chan BM; Elliott BE
J Cell Biochem; 2009 Aug; 107(6):1168-81. PubMed ID: 19533669
[TBL] [Abstract][Full Text] [Related]
25. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.
Lee WJ; Chen WK; Wang CJ; Lin WL; Tseng TH
Toxicol Appl Pharmacol; 2008 Jan; 226(2):178-91. PubMed ID: 17961621
[TBL] [Abstract][Full Text] [Related]
26. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
[TBL] [Abstract][Full Text] [Related]
27. Expression and localization of hepatocyte growth factor and its receptor c-Met in inverted papillomas.
Choi JH; Lee SH; Lee HM; Lee SH; Jung HH; Choi J; Lim HW; Lee SW; Kang SM
Acta Otolaryngol; 2006 Jul; 126(7):724-9. PubMed ID: 16803712
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors.
Aoki T; Tsukinoki K; Kurabayashi H; Sasaki M; Yasuda M; Ota Y; Watanabe Y; Kaneko A
Oral Oncol; 2006 Jan; 42(1):51-6. PubMed ID: 16139560
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
[TBL] [Abstract][Full Text] [Related]
30. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
[TBL] [Abstract][Full Text] [Related]
31. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
32. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
33. c-Met responsiveness of isolated hepatocytes evaluated in an in vitro de-differentiation model.
Boost KA; Kim HJ; Engl T; Oppermann E; Jonas D; Oertl A; Blaheta RA
Int J Mol Med; 2006 Mar; 17(3):475-82. PubMed ID: 16465395
[TBL] [Abstract][Full Text] [Related]
34. Expression and functional role of hepatocyte growth factor and its receptor (c-met) during fetal mouse testis development.
Ricci G; Catizone A; Galdieri M
J Endocrinol; 2006 Dec; 191(3):559-70. PubMed ID: 17170214
[TBL] [Abstract][Full Text] [Related]
35. NK3 and NK4 of HGF enhance filamin production via STAT pathway, but not NK1 and NK2 in human breast cancer cells.
Yin YL; Chen HL; Kuo HM; He SP
Acta Pharmacol Sin; 2008 Jun; 29(6):728-35. PubMed ID: 18501120
[TBL] [Abstract][Full Text] [Related]
36. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the met receptor in mesothelioma.
Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
[TBL] [Abstract][Full Text] [Related]
38. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W
Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
[TBL] [Abstract][Full Text] [Related]
39. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases.
Sridhar SC; Miranti CK
Oncogene; 2006 Apr; 25(16):2367-78. PubMed ID: 16331263
[TBL] [Abstract][Full Text] [Related]
40. Hepatocyte growth factor receptor, c-Met, in human embryo salivary glands. An immunohistochemical study.
Loreto C; Caltabiano R; Musumeci G; Caltabiano C; Greco MG; Leonardi R
Anat Histol Embryol; 2010 Jun; 39(3):173-7. PubMed ID: 20331593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
